{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:43:40Z","timestamp":1783356220229,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008274","name":"P. A. Messerschmidt og Hustrus Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008276","name":"Skibsreder Per Henriksen, R og Hustrus Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008276","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche a\/s"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung abnormalities (ILA) are common in participants of lung cancer screening trials and broad population-based cohorts. They are associated with increased mortality, but less is known about disease specific morbidity and healthcare utilisation in individuals with ILA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included all participants from the screening arm of the Danish Lung Cancer Screening Trial with available baseline CT scan data (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u20091990) in this cohort study. The baseline scan was scored for the presence of ILA and patients were followed for up to 12\u2009years. Data about all hospital admissions, primary healthcare visits and medicine prescriptions were collected from the Danish National Health Registries and used to determine the participants\u2019 disease specific morbidity and healthcare utilisation using Cox proportional hazards models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 332 (16.7%) participants with ILA were more likely to be diagnosed with one of several respiratory diseases, including interstitial lung disease (HR: 4.9, 95% CI: 1.8\u201313.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.008), COPD (HR: 1.7, 95% CI: 1.2\u20132.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.01), pneumonia (HR: 2.0, 95% CI: 1.4\u20132.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.001), lung cancer (HR: 2.7, 95% CI: 1.8\u20134.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.001) and respiratory failure (HR: 1.8, 95% CI: 1.1\u20133.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.03) compared with participants without ILA. These findings were confirmed by increased hospital admission rates with these diagnoses and more frequent prescriptions for inhalation medicine and antibiotics in participants with ILA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Individuals with ILA are more likely to receive a diagnosis and treatment for several respiratory diseases, including interstitial lung disease, COPD, pneumonia, lung cancer and respiratory failure during long-term follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-020-1107-0","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T21:02:59Z","timestamp":1584565379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Increased respiratory morbidity in individuals with interstitial lung abnormalities"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4395-1837","authenticated-orcid":false,"given":"Nils","family":"Hoyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde M. W.","family":"Wille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgny","family":"Wilcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asger","family":"Dirksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper H.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaigham","family":"Saghir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haseem","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saher B.","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"issue":"11","key":"1107_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1164\/rccm.201108-1420PP","volume":"185","author":"TJ Doyle","year":"2012","unstructured":"Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012 Jun 1;185(11):1147\u201353.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1107_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1183\/09031936.00201809","volume":"38","author":"N Sverzellati","year":"2011","unstructured":"Sverzellati N, Guerci L, Randi G, Calabr\u00f2 E, La Vecchia C, Marchian\u00f2 A, et al. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J. 2011 Aug;38(2):392\u2013400.","journal-title":"Eur Respir J"},{"key":"1107_CR3","first-page":"843","volume":"1","author":"JA Mackintosh","year":"2018","unstructured":"Mackintosh JA, Marshall HM, Slaughter R, Reddy T, Yang IA, Bowman RV, et al. Interstitial lung abnormalities in the queensland lung cancer screening study: prevalence and progression over two years of surveillance. Intern Med J. 2018;1:843\u20139.","journal-title":"Intern Med J"},{"issue":"11","key":"1107_CR4","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.rmed.2010.05.014","volume":"104","author":"K Tsushima","year":"2010","unstructured":"Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med. 2010;104(11):1712\u201321.","journal-title":"Respir Med"},{"issue":"5","key":"1107_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1164\/rccm.200812-1966OC","volume":"180","author":"DJ Lederer","year":"2009","unstructured":"Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, Van Beek EJR, et al. Cigarette smoking is associated with subclinical parenchymal lung disease: the multi-ethnic study of atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med. 2009 Sep 1;180(5):407\u201314.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"1107_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJMoa1007285","volume":"364","author":"GR Washko","year":"2011","unstructured":"Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011 Mar 10;364(10):897\u2013906.","journal-title":"N Engl J Med"},{"issue":"7","key":"1107_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jama.2016.0518","volume":"315","author":"RK Putman","year":"2016","unstructured":"Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315(7):672\u201381.","journal-title":"JAMA."},{"issue":"2","key":"1107_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.13120816","volume":"268","author":"GY Jin","year":"2013","unstructured":"Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, et al. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology. 2013;268(2):563\u201371.","journal-title":"Radiology."},{"issue":"6","key":"1107_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1107_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1164\/rccm.200702-254OC","volume":"176","author":"IO Rosas","year":"2007","unstructured":"Rosas IO, Ren P, Avila NA, Chow CK, Franks TJ, Travis WD, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):698\u2013705.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1107_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.201109-1618OC","volume":"185","author":"TJ Doyle","year":"2012","unstructured":"Doyle TJ, Washko GR, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med. 2012;185(7):756\u201362.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"1107_CR12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1164\/rccm.201512-2523OC","volume":"194","author":"T Araki","year":"2016","unstructured":"Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the Framingham heart study. Am J Respir Crit Care Med. 2016;194(12):1514\u201322.","journal-title":"Am J Respir Crit Care Med"},{"key":"1107_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.rmed.2018.02.001","volume":"136","author":"N Hoyer","year":"2018","unstructured":"Hoyer N, Wille MMW, Thomsen LH, Wilcke T, Dirksen A, Pedersen JH, et al. Interstitial lung abnormalities are associated with increased mortality in smokers. Respir Med. 2018;136:77\u201382.","journal-title":"Respir Med"},{"issue":"4","key":"1107_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1164\/ajrccm.150.4.7921471","volume":"150","author":"DB Coultas","year":"1994","unstructured":"Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"1107_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/CLEP.S54815","volume":"5","author":"B Ley","year":"2013","unstructured":"Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483\u201392.","journal-title":"Clin Epidemiol"},{"key":"1107_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/thoraxjnl-2018-212446","volume":"74","author":"GM Hunninghake","year":"2019","unstructured":"Hunninghake GM. Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax. 2019;74:506\u201311 thoraxjnl-2018-212446.","journal-title":"Thorax"},{"key":"1107_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00408-016-9960-6","volume":"195","author":"S Vaidya","year":"2016","unstructured":"Vaidya S, Hibbert CL, Kinter E, Boes S. Identification of key cost generating events for idiopathic pulmonary fibrosis: a systematic review. Lung. 2016;195:1\u20138.","journal-title":"Lung."},{"key":"1107_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12890-015-0165-1","volume":"16","author":"K Raimundo","year":"2016","unstructured":"Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16:2.","journal-title":"BMC Pulm Med"},{"issue":"April 2016","key":"1107_CR19","first-page":"1","volume":"6998","author":"N Wu","year":"2014","unstructured":"Wu N, Yu YF, Chuang C-C, Wang R, Benjamin NN, Coultas DB. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ. 2014;6998(April 2016):1\u201326.","journal-title":"J Med Econ"},{"issue":"5","key":"1107_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1164\/rccm.201505-1040OC","volume":"193","author":"MMW Wille","year":"2016","unstructured":"Wille MMW, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the randomized Danish lung Cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193(5):542\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1107_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1183\/09031936.05.00035205","volume":"26","author":"R Pellegrino","year":"2005","unstructured":"Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948\u201368.","journal-title":"Eur Respir J"},{"issue":"11","key":"1107_CR22","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1007\/s00330-014-3294-7","volume":"24","author":"MMW Wille","year":"2014","unstructured":"Wille MMW, Thomsen LH, Dirksen A, Petersen J, Pedersen JH, Shaker SB. Emphysema progression is visually detectable in low-dose CT in continuous but not in former smokers. Eur Radiol. 2014;24(11):2692\u20139.","journal-title":"Eur Radiol"},{"key":"1107_CR23","first-page":"663","volume":"12","author":"D Ghosh","year":"2002","unstructured":"Ghosh D, Lin DY. Marginal regression models for recurrent and terminal events. Stat Sin. 2002;12:663\u201388.","journal-title":"Stat Sin"},{"issue":"11","key":"1107_CR24","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1164\/rccm.201703-0555OC","volume":"196","author":"AJ Podolanczuk","year":"2017","unstructured":"Podolanczuk AJ, Oelsner EC, Barr RG, Bernstein EJ, Hoffman EA, Easthausen IJ, et al. High-attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults. Am J Respir Crit Care Med. 2017;196(11):1434\u201342.","journal-title":"Am J Respir Crit Care Med"},{"issue":"131","key":"1107_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1183\/09059180.00008613","volume":"23","author":"V Cottin","year":"2014","unstructured":"Cottin V, Richeldi L. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev. 2014;23(131):106\u201310.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"1107_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1183\/09031936.06.00037005","volume":"27","author":"G Raghu","year":"2006","unstructured":"Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136\u201342.","journal-title":"Eur Respir J"},{"key":"1107_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2147\/COPD.S103256","volume":"11","author":"F Bozzetti","year":"2016","unstructured":"Bozzetti F, Paladini I, Rabaiotti E, Franceschini A, Alfieri V, Chetta A, et al. Are interstitial lung abnormalities associated with COPD? A nested case-control study. Int J Chron Obstruct Pulmon Dis. 2016;11:1087\u201396.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"1107_CR28","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.chest.2017.04.185","volume":"152","author":"SY Ash","year":"2017","unstructured":"Ash SY, Harmouche R, Putman RK, Ross JC, Diaz AA, Hunninghake GM, et al. Clinical and genetic associations of objectively identified interstitial changes in smokers. Chest. 2017;152(4):780\u201391.","journal-title":"Chest."},{"issue":"6","key":"1107_CR29","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","volume":"176","author":"KF Rabe","year":"2007","unstructured":"Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532\u201355.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"1107_CR30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","volume":"68","author":"A Torres","year":"2013","unstructured":"Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057\u201365.","journal-title":"Thorax."},{"issue":"1","key":"1107_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1164\/rccm.201604-0818LE","volume":"195","author":"RK Putman","year":"2017","unstructured":"Putman RK, Hunninghake GM, Dieffenbach PB, Barragan-Bradford D, Serhan K, Adams U, et al. Interstitial lung abnormalities are associated with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195(1):138\u201341.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1107_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/MCP.0000000000000091","volume":"20","author":"SD Nathan","year":"2014","unstructured":"Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med. 2014;20(5):463\u201371.","journal-title":"Curr Opin Pulm Med"},{"issue":"10","key":"1107_CR33","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1164\/rccm.201201-0006PP","volume":"185","author":"G Raghu","year":"2012","unstructured":"Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1107_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1183\/09031936.00041411","volume":"39","author":"DB Sprunger","year":"2012","unstructured":"Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39(1):125\u201332.","journal-title":"Eur Respir J"},{"issue":"2","key":"1107_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.chest.2016.09.009","volume":"151","author":"P Ungprasert","year":"2017","unstructured":"Ungprasert P, Crowson CS, Matteson EL. Association of Sarcoidosis with Increased Risk of VTE: a population-based study, 1976 to 2013. Chest. 2017;151(2):425\u201330.","journal-title":"Chest."},{"issue":"10","key":"1107_CR36","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1164\/rccm.200912-1951OC","volume":"181","author":"BF Sode","year":"2010","unstructured":"Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med. 2010;181(10):1085\u201392.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"1107_CR37","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1164\/rccm.200805-725OC","volume":"178","author":"RB Hubbard","year":"2008","unstructured":"Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178(12):1257\u201361.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"1107_CR38","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1164\/rccm.201607-1363ED","volume":"194","author":"AU Wells","year":"2016","unstructured":"Wells AU, Kokosi MA. Subclinical interstitial lung abnormalities: toward the early detection of idiopathic pulmonary fibrosis? Am J Respir Crit Care Med. 2016;194(12):1445\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1107_CR39","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1183\/13993003.00129-2016","volume":"48","author":"AJ Podolanczuk","year":"2016","unstructured":"Podolanczuk AJ, Oelsner EC, Barr RG, Hoffman EA, Armstrong HF, Austin JHM, et al. High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. Eur Respir J. 2016;48(5):1442\u201352.","journal-title":"Eur Respir J"},{"issue":"16","key":"1107_CR40","first-page":"1","volume":"2600","author":"SLF Walsh","year":"2016","unstructured":"Walsh SLF, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini A, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016;2600(16):1\u20139.","journal-title":"Lancet Respir Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-020-1107-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T20:18:41Z","timestamp":1616098721000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-1107-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-1107-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17784\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17784\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17784\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"17 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The DLCST was approved by the Ethics Committee of Copenhagen County. Approval of data management in the trial was obtained from the Danish Data Protection Agency. All participants provided written informed consent and the study was conducted according to the principles of the Declaration of Helsinki. This follow-up study was approved by the Danish Data Protection Agency (HGH-2016-017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Hoyer reports grants from Roche a\/s, grants from Skibsreder Per Henriksen, R. og Hustrus Fond (Shipowner Per Henriksen R. and wife foundation), grants from P.A. Messerschmidt og Hustrus Fond (P.A. Messerschmidt and wife foundation) outside the submitted work. Dr. Hohw\u00fc Thomsen has nothing to disclose. Dr. Winkler Wille has nothing to disclose. Dr. Wilcke has nothing to disclose. Dr. Dirksen has nothing to disclose. Dr. Holst Pedersen has nothing to disclose. Dr. Ashraf has nothing to disclose. Dr. Saghir has nothing to disclose. Dr. Shaker reports personal fees from Roche a\/s and personal fees from Boehringer Ingelheim, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}